Respen-A is a homeopathic treatment developed by Elaine DeLack, RN, CEO of MedDEV Inc., that aims to address the core symptoms of Autism Spectrum Disorder (ASD). Available since 2009, Respen-A requires a doctor's prescription and is currently only available from three compounding pharmacies. The treatment has been endorsed by over 130 doctors and has shown significant improvements in speech, language, communication, sociability, sensory cognitive awareness, and health physical behavior in autistic patients, according to a recent clinical study conducted by Dr. Anju Usman.
Respen-A is a topical disc that is applied to the skin in the morning and removed at bedtime. It has been reported by parents to show noticeable improvements in core symptoms, with some seeing results within ten minutes of application. The treatment has gained recognition for its efficacy in improving the lives of those with ASD and is considered the world's first successful treatment for the core symptoms of autism. Despite its success, Respen-A remains relatively unknown due to limited advertising and is primarily spread through word of mouth.
Generated from the website